Biocartis
In Brief This Week: Biocartis, Quest Diagnostics, OpGen, More
News items for the week of Jan. 16, 2023.
Biocartis Reports 14 Percent Increase in Q3 Product Revenue
The Mechelen, Belgium-based molecular diagnostics developer said it has placed 189 new instruments to date this year.
Ophiomics Liver Cancer Assay Gets CE-IVD Mark
Biocartis is launching the HepatoPredict gene expression assay to help predict the benefits of liver transplant in hepatocellular carcinoma patients.
SkylineDx Gains CE-IVD Mark for Melanoma Metastasis Risk Assay
The Netherlands-based firm is partnering with Belgian company Biocartis on European commercialization of the qPCR assay, which could reduce unnecessary surgeries.
Biocartis Posts 21 Percent Jump in H1 Revenues
The company also announced a recapitalization that is expected to provide it with roughly €66 million in new capital.
Jun 22, 2022
Biocartis, AstraZeneca Ink Companion Diagnostic Pact
Jun 20, 2022
Biocartis Nabs CE Mark for Lung Cancer Test
Feb 24, 2022
Biocartis Reports 12 Percent Rise in 2021 Revenues
Sep 2, 2021
Biocartis H1 Revenues up 31 Percent
Feb 25, 2021
Biocartis Reports 15 Percent Rise in 2020 Revenues
Nov 12, 2020
Biocartis Q3 Cartridge Volume Grows 61 Percent
Nov 10, 2020